Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating [Yahoo! Finance]
TriSalus Life Sciences, Inc. (TLSI)
Company Research
Source: Yahoo! Finance
TriSalus Life Sciences, Inc. (NASDAQ: TLSI is among the 11 Fastest Growing Penny Stocks to Buy Right Now Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating On March 6, 2026, Canaccord analyst William Plovanic lowered the price target on TriSalus Life Sciences, Inc. (NASDAQ:TLSI) to $7 from $12 previously and maintained a Buy rating. William Plovanic said Q4 results came in line with the company's preannouncement and that guidance was reiterated, with 2026 expected to be back-end loaded as the company doubles its sales force. On March 5, 2026, TriSalus Life Sciences, Inc. (NASDAQ:TLSI) reported fourth-quarter EPS of (21c) versus consensus of (14c) and revenue of $13.205M compared with $8.261M in the prior year. CEO Mary Szela pointed to “strong commercial performance,” citing growing clinical adoption of the TriNav product suite and the company's proprietary PEDD platform across multiple solid tumor indications. Sze
Show less
Read more
Impact Snapshot
Event Time:
TLSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSI alerts
High impacting TriSalus Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
TLSI
News
- TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor ModelsBusiness Wire
- TriSalus Life Sciences (TLSI) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TLSI&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sMarketBeat
- TriSalus Life Sciences (TLSI) had its price target lowered by Canaccord Genuity Group Inc. from $12.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- TriSalus Life Sciences Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
TLSI
Earnings
- 3/5/26 - Miss
TLSI
Sec Filings
- 3/20/26 - Form 4
- 3/20/26 - Form 4
- 3/20/26 - Form 4
- TLSI's page on the SEC website